Outcome of first-line treatment with pembrolizumab according to KRAS/TP53 mutational status for non-squamous PD-L1 high (≥50%) NSCLC in the German National Network Genomic Medicine Lung Cancer (nNGM).

Philip Bischoff, Martin Reck,Tobias Overbeck,Petros Christopoulos,Achim Rittmeyer, Heike Lüders,Jens Kollmeier, Jonas Kulhavy, Marcel Kemper,Niels Reinmuth,Julia Röper,Melanie Janning,Linna Sommer, Lukas Aguinarte,Myriam Koch,Marcel Wiesweg,Claas Wesseler,Cornelius F Waller,Diego Kauffmann-Guerrero,Albrecht Stenzinger,Susann Stephan-Falkenau,Marcel Trautmann, Silke Lassmann,Markus Tiemann, Frederick Klauschen,Martin Sebastian,Frank Griesinger,Jürgen Wolf,Sonja Loges,Nikolaj Frost

Journal of Thoracic Oncology（2023）

引用 0|浏览20

暂无评分

摘要

G12C/TP53 co-mutations identify a subset of patients with a very favorable long-term survival with ICI monotherapy, mediated by highly active IFNγ signaling in a pro-inflammatory TME.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要